Bio-Works Technologies
Bio-Works Confirms a New Order for WorkBeads affimAb for Use in Antibody Production for 11.2 MSEK
"These orders confirm that our focus on building partnerships with our process customers is paying off," says Lone Carlbom, CEO of Bio-Works.
"This customer has now integrated WorkBeads affimAb into several processes, which reinforces that our products are of high quality and that Bio-Works brings value to our customers."
WorkBeads affimAb is a modern affinity resin well-suited for large-scale purification of monoclonal antibodies, and these orders are the result of a letter of intent that Bio-Works communicated earlier this quarter.
This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 14-01-2025 13:33 CET.
| Datum | 2025-01-14, kl 13:33 |
| Källa | Cision |
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.